How to Inject Tesamorelin: Sites, Syringes and Steps
Where to inject Tesamorelin, which syringe to use, how to read units and the hygiene steps that prevent infection.
Injection sites
Most peptides are injected under the skin (subcutaneously), into the fatty layer rather than the muscle.
- Belly: at least 2 inches (5 cm) away from the navel.
- Front and outer thighs.
- Back of the upper arms, if someone else can reach it.
- Rotate sites each time and avoid skin that is bruised, scarred or irritated.
Syringe and needle
U-100 insulin syringes are marked in units: 100 units equal 1 mL, so 10 units is 0.1 mL. They come in 0.3, 0.5 and 1 mL sizes; a smaller syringe has finer marks and is easier to read for small doses. Needle length and gauge used for Tesamorelin in studies: not reported in study abstracts (PubMed search, 11 Oct 2026).
How to read an insulin syringeStep by step
- 1Wash your handsUse soap and water, and work on a clean surface.
- 2Check the vialLabel, lot and date present; solution clear with no particles. Mixing a powder vial first? Use sterile bacteriostatic water.
- 3Clean the vial top and the siteWipe both with an alcohol swab and let them dry.
- 4Draw the dosePull the plunger to the units mark for your dose, then tap out air bubbles and re-check the mark.
- 5InjectPinch a fold of skin, insert the needle at 45 to 90 degrees, push the plunger slowly and wait a few seconds before withdrawing.
- 6Dispose safelyPut the used syringe straight into a sharps container. Never reuse or share needles.
The label allows one injection area: the abdomen
The Egrifta SV label says to inject into the abdomen, rotating between areas of the abdomen, and not into scar tissue, bruises or the navel.[6]
The Egrifta WR label gives the same site instructions.[7]
In clinical trials, injection site reactions occurred in 25% of Egrifta-treated patients and 14% of placebo-treated patients during the first 26 weeks.[6]
Two products with different vials, diluents and shelf lives
The WR label states that Egrifta WR and Egrifta SV are not substitutable.[7]
SV is a 2 mg vial reconstituted with 0.5 mL of sterile water; the label tells users to administer 0.35 mL immediately and discard the rest.[6]
WR is reconstituted with 1.3 mL of bacteriostatic water, and one reconstituted vial covers 7 consecutive daily doses of 0.16 mL.[7]
After mixing, WR is kept at room temperature, not refrigerated, and unused solution is discarded after the 7-day period.[7]
Checking the label's volumes against its concentrations: SV 1.4 mg / 4 mg per mL = 0.35 mL (35 units on a U-100 syringe); WR 1.28 mg / 8 mg per mL = 0.16 mL (16 units), and 7 x 0.16 = 1.12 mL of the 1.3 mL used per vial.
Calculated from SV concentration mg per m L 2 / 0.5 = 4; SV dose mg 1.4; WR concentration mg per m L 8; WR dose mg 1.28; WR days per vial 7; U100 units per m L 100. Formula: 1.4 / 4 = 0.35 mL x 100 = 35 units; 1.28 / 8 = 0.16 mL x 100 = 16 units; 7 x 0.16 = 1.12 mL
Storage and status
The SV label says to store the 2 mg vial at room temperature, 20°C to 25°C.[6]
An FDA warning letter lists tesamorelin among products it calls unapproved new drugs under section 505(a) of the Federal Food, Drug, and Cosmetic Act.[8]
Common questions
Where do you inject tesamorelin?
The abdomen only, according to the Egrifta labels, away from scars, bruises and the navel, with a different area of the abdomen each time.[6]
What syringe is used for Tesamorelin?
Vials are usually drawn with a U-100 insulin syringe, where 100 units equal 1 mL. Common sizes hold 0.3, 0.5 or 1 mL. Match the syringe to the dose so the mark is easy to read.
How often is Tesamorelin injected?
The interval comes from the study or prescription, not from this guide. See the dosage page for what studies used.
What is the tesamorelin injection site rule for reactions?
The label advises rotation to different abdominal areas to reduce injection-site reactions.[6]
Can a reconstituted Egrifta vial be kept in the refrigerator?
SV's label says not to freeze or refrigerate the reconstituted solution, and WR's says to store it at room temperature.[6]
More on Tesamorelin
Sources
- 1Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 2BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 3PubMed search: (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) (104 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 4PubMed search: (tesamorelin[tiab] OR TH9507[tiab]) AND (pharmacokinetic*[tiab] OR half-life[tiab]) (5 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 5PubMed search: (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (36 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 6EGRIFTA SV prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 7EGRIFTA WR prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 8Official web pageOfficial web page · web page
Found an error? Report a correction.